The quest for the treatment of cognitive impairment: α7 nicotinic and α5 GABAA receptor modulators

Expert Opinion on Therapeutic Patents

Volumn 17, Issue 11, 2007, Pages 1365-1377

  Romanelli, Maria Novella ^a   Gualtieri, Fulvio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

5; 7 nicotinic acctylcholine receptors; Cognition enhancers; GABAA receptors; Nootropic compounds

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALPHA5 4 AMINOBUTYRIC ACID A RECEPTOR; ALPHA5 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; ALPHA7 NICOTINIC RECEPTOR BLOCKING AGENT; AR R17779; BENZODIAZEPINE DERIVATIVE; BUNGAROTOXIN RECEPTOR; FG 8094; JN 403; L 655708; MEM 3454; METHYLLICACONITINE; N (4 ACETYL 1 PIPERAZINYL) 4 FLUOROBENZAMIDE; NICOTINIC AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; PHA 543613; PNU 120596; PNU 282987; PWZ 029; SPIRO[1 AZABICYCLO[2.2.2]OCTANE 3,2' THIAZOLIDINE] 2' ONE; SSR 180711; TC 5619; UNCLASSIFIED DRUG; XL 1356;

CLINICAL TRIAL; COGNITIVE DEFECT; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PATENT; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA;

EID: 36549045640     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.17.11.1365     Document Type: Review

References (64)

1. GUALTIERI F, GUANDALINI L, MANETTI D, MARTINI E, ROMANELLI MN: Cognition-enhancing drugs in mild cognitive impairment (MCI) and Alzheimer's disease (AD): an update [1]. Med. Chem. Rev. Online (2005) 2:471-487.
2. PETERSEN RC: Mild cognitive impairment as a diagnostic entity. J. Intern. Med. (2004) 256:183-194.
3. ROSEMBERG PB, JOHNSTON D, LYKETSOS CG: A clinical approach to mild cognitive impairment. Am. J. Psychiatry (2006) 163:1884-1890.
4. SCATENA R, MARTORANA GE, BOTTONI P et al.: An update on pharmacological approaches to neurodegenerative diseases. Expert Opin. Investig. Drugs (2007) 16(1):59-72.
5. BERRIDGE CW, WATERHOUSE BD: The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res. Rev. (2003) 42(1):33-84.
6. 6 receptor ligands as potential cognitive enhancers and antiobesity agents. Drug Discov. Today (2006) 11:283-299.
7. SCHMITT JA, WINGEN M, RAMAEKERS JG, EVERS EA, RIEDEL WJ: Serotonin and human cognitive performance. Curr. Pharm. Des. (2006) 12:2473-2486.
8. CHEBIB M, HANRAHAN JR, MEWETT KN, DUKE RK, JOHNSTON GAR: Ionotropic GABA receptors as therapeutic targets for memory and sleep disorders. Ann. Rev. Med. Chem. (2004) 39:13-23.
9. LEURS R, BAKKER RA, TIMMERMAN H, DE ESCH IJ: The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat. Rev. Drug Discov. (2005) 4:107-120.
10. ROBBINS TW, MURPHY ER: Behavioural pharmacology: 40+ years of progress, with a focus on glutamate receptors and cognition. Trends Pharmacol. Sci. (2006) 27(3):141-148.
11. EL-GHUNDI M, O'DOWD BF, GEORGE SR: Insights into the role of dopamine receptor systems in learning and memory. Rev. Neurosci. (2007) 18:37-66.
12. SARTER M: Preclinical research into cognition enhancers. Trends Pharmacol. Sci. (2006) 27:602-608.
13. JELIC V, KIVIPELTO M, WINBLAD B: Clinical trials in mild cognitive impairment: lessons for the future. J. Neurol. Neurosurg. Psychiatry (2006) 77:429-438.
14. GROSSMAN H, BERGMANN C, PARKER S: Dementia: a brief review. Mt Sinai J. Med. (2006) 73:895-992.
15. TERRY AV, BUCCAFUSCO JJ: The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J. Pharmacol. Exp. Ther. (2003) 306:821-827.
16. FISHER A, PITTEL Z, HARING R et al.: M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy. J. Mol. Neurosci. (2003) 20:349-356.
17. ROMANELLI MN, GRATTERI P, GUANDALINI L et al.: Central nicotinic receptors: structure, function, ligands, and therapeutic potential. ChemMedChem (2007) 2:746-767.
18. LEVIN ED, MCCLERNON FJ, REZVANI AH: Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (2006) 184:523-539.
19. BRIGGS CA, ANDERSON DJ, BRIONI JD et al.: Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol. Biochem. Behav. (1997) 57(1-2):231-241.
20. NANRI M, MIYAKE H, MURAKAMI Y, MATSUMOTO K, WATANABE H: GTS-21, a nicotinic agonist, attenuates multiple infarctions and cognitive deficit caused by permanent occlusion of bilateral common carotid arteries in rats. Jpn. J. Pharmacol. (1998) 78:463-469.
21. NANRI M, YAMAMOTO J, MIYAKE H, WATANABE H: Protective effect of GTS-21, a novel nicotinic receptor agonist, on delayed neuronal death induced by ischemia in gerbils. Jpn. J. Pharmacol. (1998) 76:23-29.
22. KEM WR: The brain α7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav. Brain Res. (2000) 113:169-181.
23. KEM WR, SOTI F, WILDEBOER K et al.: The nemertine toxin anabaseine and its derivative DMXBA (GTS-21): chemical and pharmacological properties. Mar. Drugs (2006) 4:255-273.
24. KITAGAWA H, TAKENOUCHI T, AZUMA R et al.: Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology (2003) 28:542-551.
25. LEVIN ED, BETTEGOWDA C, BLOSSER J, GORDON J: AR-R17779, an α7 nicotinic agonist, improves learning and memory in rats. Behav. Pharmacol. (1999) 10:675-680.
26. VAN KAMPEN M, SELBACH K, SCHNEIDER R et al.: AR-R 17779 improves social recognition in rats by activation of nicotinic α7 receptors. Psychopharmacology (2004) 172:375-383.
27. MARTIN LF, KEM WR, FREEDMAN R: α-7 Nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (2004) 174:54-64.
28. OLINCY A, HARRIS JG, JOHNSON LL et al.: Proof-of-concept trial of an α7 nicotinic agonist in schizophrenia. Arch. Gen. Psychiatry (2006) 63:630-638.
29. JONNALA RR, BUCCAFUSCO JJ: Relationship between the increased cell surface α7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists. J. Neurosci. Res. (2001) 66:565-572.
30. SHIMOHAMA S, GREENWALD DL, SHAFRON DH et al.: Nicotinic α7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage. Brain Res. (1998) 779:359-363.
31. GROTTICK AJ, TRUBE G, CORRIGALL WA et al.: Evidence that nicotinic α7 receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J. Pharmacol. Exp. Ther. (2000) 294(3):1112-1119.
32. MAZUROV A, HAUSER T, MILLER CH: Selective α7 nicotinic acetylcholine receptor ligands. Curr. Med. Chem. (2006) 13:1567-1584.
33. BODNAR AL, CORTES-BURGOS LA, COOK KK et al.: Discovery and structure-activity relationship of quinuclidine benzamides as agonists of α7 nicotinic acetylcholine receptors. J. Med. Chem. (2005) 48(4):905-908.
34. WISHKA DG, WALKER DP, YATES KM et al.: Discovery of N-[(3 R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the α7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure-activity relationship. J. Med. Chem. (2006) 49:4425-4436.
35. BOESS FG, DE VRY J, ERB C et al.: The novel {α}7 nicotinic acetylcholine receptor agonist N-[(3R)-1-Azabicyclo [2.2.2]oct-3-yl]-7-[2- (methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents. J. Pharmacol. Exp. Ther. (2007)321(2):716-725.
36. 3 receptor. Bioorg. Med. Chem. Lett. (2005) 15(21):4727-4730.
37. BITON B, BERGIS OE, GALLI F et al.: SSR180711, a novel selective [α]7 nicotinic receptor partial agonist. (1) Binding and functional profile. Neuropsychopharmacology (2007) 32(1):1-16.
38. FEUERBACH D, NOZULAK J, LINGENHOEHL K, MCALLISTER K, HOYER D: JN403, in vitro characterization of a novel nicotinic acetylcholine receptor α7 selective agonist. Neurosci. Lett. (2007) 416:61-65.
39. MAZUROV A, KLUCIK J, MIAO L et al.: 2-(Arylmethyl)-3-substituted quinuclidines as selective α7 nicotinic receptor ligands. Bioorg. Med. Chem. Lett. (2005) 15(8):2073-2077.
40. PICHAT P, BERGIS OE, TERRANOVA J-P et al.: SSR180711, a Novel Selective [α]7 nicotinic receptor partial agonist. (II) Efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology (2007) 32(1):17-34.
41. HAJOS M, HURST RS, HOFFMANN WE et al.: The selective α7 nicotinic acetylcholine receptor agonist PNU-282987 i N-[(3R)-1-azabicyclo [2.2.2]oct-3-yl] -4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J. Pharmacol. Exp. Ther. (2005) 312:1213-1222.
42. CILIA J, CLUDERAY JE, ROBBINS MJ et al.: Reversal of isolation-rearing-induced PPI deficits by an α7 nicotinic receptor agonist. Psychopharmacology (2005) 182:214-219.
43. JORDAN KG, GATTO GJ, HAUSER TA, BENCHERIF M: Assessment of a full α7 nicotinic acetylcholine receptor agonist, TC-5619, in animal models of schizophrenia. 35th Annual Meeting of Society for Neuroscience, Washington, DC, USA (12-15 November 2005) Program No. 952.10. 2005 Abstract Viewer/Itinerary Planner.
44. TATSUMI R, FUJIO M, TAKANASHI S et al.: (R)-3′-(3-Methylbenzo[b] thiophen-5-yl)spiro[1-azabicyclo [2,2,2] octane-3,5′-oxazolidin]-2′-one, a novel and potent α7 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties. J. Med. Chem. (2006) 49:4374-4383.
45. MARRERO MB, PAPKE RL, BHATTI BS, SHAW S, BENCHERIF M: The neuroprotective effect of 2-(3-pyridyl)-1-azabicyclo[3.2.2] nonane (TC-1698), a novel α7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase. J. Pharmacol. Exp. Ther. (2003) 309:16-27.
46. HURST RS, HAJOS M, RAGGENBASS M et al.: A novel positive allosteric modulator of the α7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J. Neurosci. (2005) 25:4396-4405.
47. NG HJ, WHITTEMORE ER, TRAN MB et al.: Nootropic {α}7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc. Natl. Acad. Sci. USA (2007) 104(19):8059-8064.
48. YAMAZAKI M, MATSUOKA N, MAEDA N, OHKUBO Y, YAMAGUCHI I: FK960 N-(4-acetyl-1-piperazinyl) -p-fluorobenzamide monohydrate ameliorates the memory deficits in rats through a novel mechanism of action. J. Pharmacol. Exp. Ther. (1996) 279(3):1157-1173.
49. MAUBACH KA: The GABAA receptor as a potential target for the treatment of cognitive dysfunction. Drugs Future (2006) 31:151-162.
50. SIEGHART V: GABA-A receptors as targets for different classes of drugs. Drugs Future (2006) 31:685-694.
51. CHENG VY, MARTIN LJ, ELLIOTT EM et al.: α5 GABA-A receptors mediate the amnestic but not sedative-hypnotic effects of the general anesthetic etomidate. J. Neurosci. (2006) 26:3713-3720.
52. MAUBACH KA: GABA-A receptor subtype selective cognition enhancers. Curr. Drug Targets CNS Neurol. Disord. (2003) 2:233-239.
53. 3H]L-655,708, a novel ligand selective for the benzodiazepine site of GABA-A receptors which contain the α5 subunit. Neuropharmacology (1996) 35:1331-1335.
54. ATACK JR, BAVLEV PJ, SEABROOK GR et al.: L-655,708 enhances cognition in rats but is not proconvulsant at doses selective for α5 containing GABA-A receptors. Neurpharmacology (2006) 51:1023-1029.
55. STERNFELD F, CARLING WR, JELLEY RA et al.: Selective, orally active γ-aminobutyric acid α5 receptor inverse agonists as cognition enhancers. J. Med. Chem. (2004) 47:2176-2179.
56. DAWSON GR, MAUBACH KA, COLLINSON N et al.: An inverse agonist selective for α5 subunit-containing GABA-A recptors enhance cognition. J. Pharmacol. Exp. Ther. (2006) 316:1335-1345.
57. STREET LJ, STERNFELD F, JELLEY AR et al.: Synthesis and biological evaluation of 3-heterocyclyl-7,8,9,10-tetrahydro- (7,10-ethano)-1,2,4-triazolo [3,4-a]phtalazines and analogues as subtype selective inverse agonists for the GABA-A α5 benzodiazepine binding site. J. Med. Chem. (2004) 47:3642-3657.
58. COLLINSON N, ATACK JR, LAUGHTON P, DAWSON GR, STEPHENS DN: An inverse agonist selective for α5 subunit containing GABA-A receptors improves encoding and recall but not consolidation in the Morris water maze. Psychopharmacology (2006) 188:619-628.
59. CHAMBERS MS, JONES P, CARLING WR et al.: An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABA-A α5 receptors with cognition enhancing properties. J. Med. Chem. (2004) 47:5829-5832.
60. JONES P, ATACK JR, BRAUN M et al.: Pharmacokinetics and metabolism studies on (3-tert-butyl-7- (5-methylisoxazol-3-yl)-2- (1-methyl-1H-1,2,4- triazol-5-ylmethoxy) pyrazolo[1,5-d][1,2,4] triazine, a functionally selective GABA-A α5 inverse agonist for cognitive dysfunction. Bioorg. Med. Chem. Lett. (2006) 16:872-875.
61. O'CONNOR D, JONES P, CHAMBERS MS et al.: Aldehyde oxidase and its contribution to the metabolism of a structurally novel, functionally selective GABA-A α5-subtype inverse agonist. Xenobiotica (2006) 36:315-330.
62. HOGENKAMP DJ, JOHNSTONE TBC, HUANG JC et al.: Enaminone amides as novel orally active GABA-A receptor modulators. J. Med. Chem. (2007) 50:3369-3379.
63. JOHNSTON GAR, CHEBIB M, HANRAHAN JR, MEWETT KN: GABA(C) receptors as drug targets. Curr. Drug Targets CNS Neurol. Disord. (2003) 2:260-268.
64. CHEBIB M, HANRAHAN JR, KUMAR RJ et al.: (3-Aminocyclopentyl)m ethylphosphinic acids: novel GABA-C receptor antagonists. Neuropharmacology (2007) 52:779-787.